Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a descriptive cohort study within the OpenSAFELY platform

Background: Patients surviving hospitalisation for COVID-19 are thought to be at high risk of cardiometabolic and pulmonary complications, but quantification of that risk is limited. We aimed to describe the overall burden of these complications in people after discharge from hospital with COVID-19. Methods: Working on behalf of NHS England, we used linked primary care records, death certificate and hospital data from the OpenSAFELY platform. We constructed three cohorts: patients discharged following hospitalisation with COVID-19, patients discharged following pre-pandemic hospitalisation with pneumonia, and a frequency-matched cohort from the general population in 2019. We studied seven outcomes: deep vein thrombosis (DVT), pulmonary embolism (PE), ischaemic stroke, myocardial infarction (MI), heart failure, AKI and new type 2 diabetes mellitus (T2DM) diagnosis. Absolute rates were measured in each cohort and Fine and Gray models were used to estimate age/sex adjusted subdistribution hazard ratios comparing outcome risk between discharged COVID-19 patients and the two comparator cohorts. Results: Amongst the population of 77,347 patients discharged following hospitalisation with COVID-19, rates for the majority of outcomes peaked in the first month post-discharge, then declined over the following four months. Patients in the COVID-19 population had markedly higher risk of all outcomes compared to matched controls from the 2019 general population. Across the whole study period, the risk of outcomes was more similar when comparing patients discharged with COVID-19 to those discharged with pneumonia in 2019, although COVID-19 patients had higher risk of T2DM (15.2 versus 37.2 [rate per 1,000-person-years for COVID-19 versus pneumonia, respectively]; SHR, 1.46 [95% CI: 1.31 - 1.63]). Conclusions: Risk of cardiometabolic and pulmonary adverse outcomes is markedly raised following discharge from hospitalisation with COVID-19 compared to the general population. However, excess risks were similar to those seen following discharge post-pneumonia. Overall, this suggests a large additional burden on healthcare resources.

[1]  Panteleimon G. Takis,et al.  Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study , 2021, The Lancet.

[2]  A. Banerjee,et al.  Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study , 2021, BMJ.

[3]  K. Bhaskaran,et al.  Changes in the rate of cardiometabolic and pulmonary events during the COVID-19 pandemic , 2021, medRxiv.

[4]  L. Smeeth,et al.  Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study , 2021, The Lancet Digital Health.

[5]  C. Catena,et al.  Short-term cardiac outcome in survivors of COVID-19: a systematic study after hospital discharge , 2021, Clinical Research in Cardiology.

[6]  G. Wagener,et al.  Mortality and renal outcomes of patients with severe COVID-19 treated in a provisional intensive care unit , 2020, Journal of Critical Care.

[7]  Changwei Liu,et al.  COVID-19 AND VENOUS DISEASE , 2022 .

[8]  D. Gopalan,et al.  Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19 , 2020, The Lancet Respiratory Medicine.

[9]  S. Nopp,et al.  Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis , 2020, Research and Practice in Thrombosis and Haemostasis.

[10]  Benjamin S. Glicksberg,et al.  AKI in Hospitalized Patients with COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.

[11]  M. Landray,et al.  COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England , 2020, The Lancet.

[12]  K. Bhaskaran,et al.  OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.

[13]  S. Chakraborty,et al.  A Practical Overview and Reporting Strategies for Statistical Analysis of Survival Studies. , 2020, Chest.

[14]  Jeffrey J. Goldberger,et al.  COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors , 2020, Heart Rhythm.

[15]  P. Lamendola,et al.  COVID-19 and thrombotic complications: Pulmonary thrombosis rather than embolism? , 2020, Thrombosis Research.

[16]  D. Klonoff,et al.  Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States , 2020, Journal of diabetes science and technology.

[17]  Huihui Ren,et al.  Clinical characteristics and outcomes of patients with severe covid-19 with diabetes , 2020, BMJ Open Diabetes Research & Care.

[18]  C. Siu,et al.  Short- and potential long-term adverse health outcomes of COVID-19: a rapid review , 2020, Emerging microbes & infections.

[19]  F. Meziani,et al.  Immunohaemostasis: a new view on haemostasis during sepsis , 2017, Annals of Intensive Care.

[20]  Jason P Fine,et al.  Practical recommendations for reporting Fine‐Gray model analyses for competing risk data , 2017, Statistics in medicine.

[21]  Mei-Jie Zhang,et al.  Checking Fine and Gray subdistribution hazards model with cumulative sums of residuals , 2014, Lifetime Data Analysis.

[22]  Radford,et al.  Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis , 2020 .